Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mario Campone

Showing results (121-130 of 302) with videos related to

Pageof 31
Sort By:
Breast Cancer Research and Treatment|December 17, 2017
Efficacy of palbociclib plus fulvestrant after everolimus in hormone receptor-positive metastatic breast cancerPauline du Rusquec, Clément Palpacuer, Loic Campion, et al.
Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference|September 10, 2022
Influence of inputs for bone lesion segmentation in longitudinal <sup>18</sup>F-FDG PET/CT imaging studiesNoemie Moreau, Caroline Rousseau, Constance Fourcade, et al.
Breast Cancer Research and Treatment|February 25, 2022
Ribociclib plus letrozole in male patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: subgroup analysis of the phase IIIb CompLEEment-1 trialMario Campone, Michelino De Laurentiis, Claudio Zamagni, et al.
Cancer Genomics & Proteomics|August 10, 2019
Gene Expression Profiles Discriminate between Pathological Complete Response and Resistance to Neoadjuvant FEC100 in Breast CancerMarie Millour, Catherine Charbonnel, Florence Magrangeas, et al.
Breast Cancer Research and Treatment|November 21, 2008
A 38-gene expression signature to predict metastasis risk in node-positive breast cancer after systemic adjuvant chemotherapy: a genomic substudy of PACS01 clinical trialPascal Jézéquel, Mario Campone, Henri Roché, et al.
British Journal of Clinical Pharmacology|December 30, 2015
Influence of tumour burden on trastuzumab pharmacokinetics in HER2 positive non-metastatic breast cancerGuillemette Bernadou, Mario Campone, Jean-Louis Merlin, et al.
Biomedicines|January 8, 2025
Learning to Train and to Explain a Deep Survival Model with Large-Scale Ovarian Cancer Transcriptomic DataElena Spirina Menand, Manon De Vries-Brilland, Leslie Tessier, et al.
Cancers|January 11, 2022
Automatic Segmentation of Metastatic Breast Cancer Lesions on <sup>18</sup>F-FDG PET/CT Longitudinal Acquisitions for Treatment Response AssessmentNoémie Moreau, Caroline Rousseau, Constance Fourcade, et al.
Current Clinical Pharmacology|November 16, 2011
Unexpected high levels of vorinostat when combined with vinorelbine in patients with advanced cancerPeggy Gandia, Cecile Arellano, Quentin Chalret du Rieu, et al.
Breast Cancer Research and Treatment|May 8, 2013
A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancerHope S Rugo, Mario Campone, Dino Amadori, et al.
Pageof 31

Showing results (121-130 of 302) with videos related to

Sort By:
Pageof 31
Breast Cancer Research and Treatment|December 17, 2017
Efficacy of palbociclib plus fulvestrant after everolimus in hormone receptor-positive metastatic breast cancerPauline du Rusquec, Clément Palpacuer, Loic Campion, et al.
Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference|September 10, 2022
Influence of inputs for bone lesion segmentation in longitudinal <sup>18</sup>F-FDG PET/CT imaging studiesNoemie Moreau, Caroline Rousseau, Constance Fourcade, et al.
Breast Cancer Research and Treatment|February 25, 2022
Ribociclib plus letrozole in male patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: subgroup analysis of the phase IIIb CompLEEment-1 trialMario Campone, Michelino De Laurentiis, Claudio Zamagni, et al.
Cancer Genomics & Proteomics|August 10, 2019
Gene Expression Profiles Discriminate between Pathological Complete Response and Resistance to Neoadjuvant FEC100 in Breast CancerMarie Millour, Catherine Charbonnel, Florence Magrangeas, et al.
Breast Cancer Research and Treatment|November 21, 2008
A 38-gene expression signature to predict metastasis risk in node-positive breast cancer after systemic adjuvant chemotherapy: a genomic substudy of PACS01 clinical trialPascal Jézéquel, Mario Campone, Henri Roché, et al.
British Journal of Clinical Pharmacology|December 30, 2015
Influence of tumour burden on trastuzumab pharmacokinetics in HER2 positive non-metastatic breast cancerGuillemette Bernadou, Mario Campone, Jean-Louis Merlin, et al.
Biomedicines|January 8, 2025
Learning to Train and to Explain a Deep Survival Model with Large-Scale Ovarian Cancer Transcriptomic DataElena Spirina Menand, Manon De Vries-Brilland, Leslie Tessier, et al.
Cancers|January 11, 2022
Automatic Segmentation of Metastatic Breast Cancer Lesions on <sup>18</sup>F-FDG PET/CT Longitudinal Acquisitions for Treatment Response AssessmentNoémie Moreau, Caroline Rousseau, Constance Fourcade, et al.
Current Clinical Pharmacology|November 16, 2011
Unexpected high levels of vorinostat when combined with vinorelbine in patients with advanced cancerPeggy Gandia, Cecile Arellano, Quentin Chalret du Rieu, et al.
Breast Cancer Research and Treatment|May 8, 2013
A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancerHope S Rugo, Mario Campone, Dino Amadori, et al.
Pageof 31